Seeking Alpha
About this author: By this author:
Submit
an article to

St. Jude Medical (STJ) took a nasty beating last month as their earnings outlook and several analyst downgrades. Yesterday we saw the first upgrade – all the way to a buy. This is creating a short-squeeze as it passes above resistance and creates a fill-the-gap scenario.

October downgrades:

Even so, we picked up shares in October, after the sell-off, and added to the position today as the the price broke above resistance. Technically this stock is poised to move higher and the fundamentals are showing a positive outlook.

STJ

According to Bloomberg:

St Jude Medical Inc was rated new “Buy” at Morgan Joseph by equity analyst Bruce Jackson. The target price is $42.00 per share. Risks to attaining our price target include the timing and success of clinical trials, new product launch timing, availability of reimbursement, litigation, and healthcare reform…St. Jude Medical aims to deliver 15% EPS growth with a combination of new products, operating expense leverage, and share buybacks. Key factors in the diversified growth strategy are market share gains in cardiac rhythm management (CRM), continued growth in AF and neuromodulation, and acquired growth from Radi’s PressureWire.”

stjude

___

Disclosure: Horowitz & Company clients may hold positions of securities mentioned as of the date published.

Print this article
Comments
1
     
  • Less than 2% of the float are shorted. The stock went up because of MDT earnings and people like the author buying/adding.
    PS I bought on the author's initinal recommendation but ready to sell at 38.
    2009 Nov 25 01:25 PM Reply